Promising results from the phase 1 portion of the ZUMA-1 study, which uses chimeric antigen receptor (CAR) modified T cells to treat b-cell lymphoma patients, were published in the January issue of Molecular Therapy, the official journal of the American...
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2jbH9jw
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Publication date: April 2017 Source: European Journal of Cancer, Volume 75 Author(s): A. Ieni, G. Angelico, P. Zeppa, G. Tuccari fro...
-
Objective A systematic review and meta-analysis to investigate the impact of electronic nicotine delivery systems (ENDS) and/or electronic n...
-
Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers British Journal of Cancer 116, 1425 (23 May 2017). ...
-
Precision design of nanomedicines to restore gemcitabine chemosensitivity for personalized pancreatic ductal adenocarcinoma treatment. ...
-
Publication date: October 2017 Source: International Journal of Biological Macromolecules, Volume 103 Author(s): Shehwaz Anwar, Hina Youn...
-
Abstract The quantitative evaluation of Social Science and Humanities (SSH) and the investigation of the existing similarities between SSH...
-
Related Articles Modulation of the Tumor Microenvironment by Epstein-Barr virus Latent Membrane Protein-1 in Nasopharyngeal Carcinoma....
-
Publication date: Available online 10 March 2018 Source: Radiotherapy and Oncology Author(s): Igor Shuryak, Eric J. Hall, David J. Bre...
-
Sporadic Salmonella outbreaks with varying clinical presentations have been on the rise in various parts of Uganda. The sources of outbreaks...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου